EE434 An Economic Model to Estimate Costs of Adverse Events in Patients Treated With Lisocabtagene Maraleucel (liso-cel), Axicabtagene Ciloleucel (axi-cel), or Tisagenlecleucel (tisa-cel) for Relapsed/Refractory Follicular Lymphoma
Jul 1, 2025, 00:00
10.1016/j.jval.2025.04.2032
https://www.valueinhealthjournal.com/article/S1098-3015(25)02161-8/fulltext
Title :
EE434 An Economic Model to Estimate Costs of Adverse Events in Patients Treated With Lisocabtagene Maraleucel (liso-cel), Axicabtagene Ciloleucel (axi-cel), or Tisagenlecleucel (tisa-cel) for Relapsed/Refractory Follicular Lymphoma
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(25)02161-8&doi=10.1016/j.jval.2025.04.2032
First page :
Section Title :
Open access? :
No
Section Order :
10211